Oramed Pharmaceuticals Inc.
ORMP
$2.74
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 2.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 2.00M | -- | -- |
| Cost of Revenue | -- | -- | 1.99M | -- | -- |
| Gross Profit | -- | -- | 13.00K | -- | -- |
| SG&A Expenses | 1.27M | 1.46M | 2.31M | 2.13M | 847.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.43M | 2.49M | 6.50M | 3.60M | 3.09M |
| Operating Income | -2.43M | -2.49M | -4.50M | -3.60M | -3.09M |
| Income Before Tax | 59.45M | 13.13M | -7.06M | -9.78M | -18.51M |
| Income Tax Expenses | 11.06M | -126.00K | 584.00K | 416.00K | 1.13M |
| Earnings from Continuing Operations | 48.39M | 13.26M | -7.64M | -10.20M | -19.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.00K | 28.00K | -- | 10.00K | 23.00K |
| Net Income | 48.40M | 13.29M | -7.64M | -10.19M | -19.62M |
| EBIT | -2.43M | -2.49M | -4.50M | -3.60M | -3.09M |
| EBITDA | -2.40M | -2.46M | -4.47M | -3.56M | -3.04M |
| EPS Basic | 1.16 | 0.32 | -0.19 | -0.25 | -0.48 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.05 | -0.04 | -0.03 |
| EPS Diluted | 1.13 | 0.31 | -0.19 | -0.26 | -0.48 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.05 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 41.76M | 41.74M | 41.23M | 40.67M | 40.90M |
| Average Diluted Shares Outstanding | 42.77M | 42.61M | 41.23M | 40.67M | 40.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |